UK Parkinson's Disease Consortium - UKPDC
- Principal Investigators
- Research Groups
- Degenerating neurons
- Department of Molecular Neuroscience, UCL
- Department of Clinical Neuroscience, UCL
- MRC Protein Phosphorylation Unit, Dundee
- MRC Centre for Developmental and Biomedical Genetics, Sheffield
- Eisai Ltd
- Clinical Movement Disorders Group, UCL
- MRC Centre for Neuromuscular Diseases, UCL
- Neurodegeneration, UCL
- Neurophysiology of Human Development, UCL
- Pathophysiology of Human Movement Disorders, UCL
- Queen Square Brain Bank, UCL
- Reta Lila Weston Institute of Neurological Studies, UCL
- Sobell Department of Motor Neuroscience and Movement Disorders, UCL
- Unit of Functional Neurosurgery, UCL
- UCL Consortium for Mitochondrial Research
- UCL Genetics Institute (UGI)
- UCL Genomics
- Neurogenetics Unit, UCLH
- Neurometabolic Unit, UCLH
- Lysosomal Storage Disorders Unit, Royal Free
- School of Medicine and Dentistry, Aberdeen
- PD Med, Birmingham
- Cambridge Bristol Toronto Hamburg Neurodegenerative Disease Consortium
- Cambridge Centre for Brain Repair
- The Movement Disorders Group, Cambridge
- MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff
- MRC Centre for Regenerative Medicine, Edinburgh
- MRC Sudden Death Brain and Tissue Bank, Edinburgh
- The Institute of Cancer Research
- Bioinformatics, Statistical Genetics & Epigenetics, KCL
- MRC Toxicology Unit, Leicester
- Wellcome Trust Case Control Consortium
- WT/MRC Neurodegenarative Diseases Initiative
- Wellcome Trust Sanger Institute
- AMC Department of Neurology, Amsterdam
- Department of Clinical Genetics, VUMC
- Laboratory of Neurogenetics, NIA/NIH
- French National Institute of Health and Medical Research (Inserm)
- Brain & Spine Institute, Paris
- Centre-de-Physiopathologie-de-Toulouse-Purpan (CPTP)
- Department for Neurodegenerative Diseases, Tübingen
- Contact us
Public lecture: The autophagy signaling network, c-‐myc and pathology: don't mess with the cell cycle!
You are invited to a public lecture by Francesco Cecconi, an eminent scientist in the field of autophagy and neurodegeneration, on Thursday the 25th of April at 17:00, in the lecture theatre of 33 Queen Square, University College Hospital London, WC1N. The lecture will be followed by a general discussion with drinks and food. More...
Have you ever wondered how scientists research the brain? Have you wondered who digs through that beautiful mass of grey matter between our ears to understand how it works and why it stops working? Meet the Neurodegenerative Diseases Initiative. Funded by the Wellcome Trust and MRC, this team of scientists from around the globe investigates Alzheimer's, Parkinson's and Motor Neuron Diseases. The team is on the hunt for understanding and treatments for brain diseases. More...
The "Degenerating Brains" public symposium was held on the 13th March 2013, as part of Brain Awareness Week. Around 250 people showed up to hear Professors John Hardy (UCL), Chris Shaw (KCL) and David Rubinsztein (Cambridge) discuss new discoveries in neurodegenerative diseases and how they might impact drug treatment. More...
New research, published in Neuron, gives insight into how single mutations in the VCP gene cause a range of neurological conditions including a form of dementia called Inclusion Body Myopathy, Paget’s Disease of the Bone and Frontotemporal Dementia (IBMPFD), and the motor neuron disease Amyotrophic Lateral Sclerosis (ALS). More...
You are invited to an evening (13th March 2013) exploring the very latest in cutting edge research into neurodegenerative diseases. Supported by the Wellcome Trust, scientists investigating Alzheimer's, Parkinson's and Motor Neuron disease will explain how our understanding of these disorders is changing in the light of new discoveries in genetics and cell biology, and how these discoveries impact on developing new drugs for these diseases.
18.00 Welcome and introduction
18.10 Lectures commence
PD Med, Birmingham
PD Med, University of Birmingham, is a large, simple, "real-life" trial that aims to determine much more reliably which class of drugs provides the most effective control, with the fewest side-effects, for both early and later Parkinson's Disease (PD). Patients with early PD are randomised between DA, MAOBI and LD alone, with the option to omit either the MAOBI or LD alone arm. Those with later PD are randomised between COMTI, DA and MAOBI, with the option to omit either the DA or the MAOBI arm. The main outcome measure is patient-rated quality of life, using the PDQ-39 scale, which assesses all aspects of the patient’s life, and is sensitive to changes considered important to patients but not identified by clinical ratings.
In order to recruit the large number of patients needed to provide reliable answers, and to maximise the clinical relevance of the findings, the trial is designed to fit in with routine practice as far as possible and to impose minimal additional workload: clinicians can use the specific drug within each class that they prefer, treatments are prescribed in the usual way, and extra clinic-based tests and evaluations have been kept to a minimum (the majority of assessments are by postal questionnaires to patients and carers). Because the success of the trial depends entirely on the whole-hearted collaboration of a large number of doctors, nurses and others, publication of the main result will be in the name of the collaborative group and not those of the central organisers.
Page last modified on 23 mar 11 16:08